MedTrace Logo

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

NCT01810185 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-11-20

No results posted yet for this study

Summary

The investigators will be looking at the efficacy of the use of once daily use of low dose naltrexone (4.5mg) in subjects with symptomatic inflammatory bowel disease.

Conditions

Interventions

DRUG

Low dose naltrexone

4.5 mg daily for 12 weeeks

DRUG

Placebo

Sponsors & Collaborators

  • Santa Barbara Cottage Hospital

    lead OTHER

Principal Investigators

  • Erick J Imbertson, M.D. · Santa Barabara Cottage Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01810185 on ClinicalTrials.gov